SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, Abishek, Liu, Jinyan, Martinot, Amanda J., McMahan, Katherine, Mercado, Noe B., Peter, Lauren, Tostanoski, Lisa H., Yu, Jingyou +45 more·2020·Science
DOI 10.1126/science.abc4776

Cited by (785)

Items 201–300 of 785

  1. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity
    S. Nielsen, Line K. Vibholm, Ida Monrad, R. Olesen, Giacomo S. Frattari, M. H. Pahus, J. F. Højen, J. Gunst, C. Erikstrup, Andreas Holleufer et al. · 2020 · bioRxiv
  2. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID
    Denise Goh, J. Lim, Sonia Bilbao Fernaíndez, C. Joseph, Sara Gil Edwards, Z. W. Neo, J. Lee, Sílvia Guerrero Caballero, Mai-Chan Lau, Joe Poh-Sheng Yeong · 2022 · Frontiers in Immunology
  3. Animal models for SARS-CoV-2
    Chung-Young Lee, Anice C. Lowen · 2021 · Current Opinion in Virology
  4. Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission
    Young-Il Kim, Se-Mi Kim, Su-Jin Park, Eun-Ha Kim, Kwang-Min Yu, Jae-Hyung Chang, Eun Ji Kim, Mark Anthony B. Casel, Rare Rollon, Seung-Gyu Jang et al. · 2021 · Emerging Microbes and Infections
  5. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters
    R. Brocato, Lucia M. Principe, Robert K. Kim, Xian-Kun Zeng, Janice A. Williams, Ya-Nan Liu, Rong Li, Jeffrey M. Smith, J. Golden, Dave Gangemi et al. · 2020 · Journal of Virology
  6. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
    Carly G.K. Ziegler, Vincent N. Miao, Anna H. Owings, Andrew W. Navia, Ying Tang, Joshua D. Bromley, Peter Lotfy, Meredith Sloan, Hannah Laird, Haley B. Williams et al. · 2021 · Cell
  7. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
    Cillian Gartlan, T. Tipton, F. Salguero, Q. Sattentau, A. Gorringe, M. Carroll · 2022 · Frontiers in Immunology
  8. A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients
    Allison N. Grossberg, Lilia A. Koza, Aurélie Ledreux, C. Prusmack, H. Krishnamurthy, V. Jayaraman, A. Granholm, D. Linseman · 2021 · Nature Communications
  9. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model
    Ami R. Patel, Jewell N. Walters, E. Reuschel, K. Schultheis, Elizabeth M. Parzych, E. Gary, I. Maričić, M. Purwar, Zeena Eblimit, Susanne N. Walker et al. · 2020 · bioRxiv
  10. COVID-19 Immunity Passport to Ease Travel Restrictions?
    Lin H. Chen, D. Freedman, L. Visser · 2020 · Journal of Travel Medicine
  11. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
    Xue-Qiao Liu, Cindy Luongo, Y. Matsuoka, Hong-Su Park, Celia Santos, Li-Juan Yang, Ian N. Moore, Sharmin Afroz, Reed F. Johnson, B. Lafont et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  12. Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
    Matthew K. Siggins, Ryan S. Thwaites, Peter Openshaw · 2021 · Trends in Microbiology
  13. Severe Acute Respiratory Syndrome Coronavirus 2
    M. Marks, Geraldine O'Hara, C. Houlihan, L. Bell, M. Heightman, Nicholas Hart · 2021 · Encyclopedia of Respiratory Medicine
  14. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
    F. Chiuppesi, V. Nguyen, Yoonsuh Park, Heidi Contreras, Veronica Karpinski, Katelyn Faircloth, Jenny Nguyen, Mindy Kha, Daisy Johnson, Joybelle Martinez et al. · 2021 · npj Vaccines
  15. SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study
    T. Prince, Shirley L. Smith, A. Radford, T. Solomon, G. Hughes, E. I. Patterson · 2021 · Viruses
  16. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
    R. Houot, R. Levy, G. Cartron, P. Armand · 2020 · European Journal of Cancer
  17. The Laboratory Diagnosis of COVID-19-- Frequently-Asked Questions
    Ferric C. Fang, S. Naccache, Alexander L. Greninger · 2020 · Clinical Infectious Diseases
  18. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2–experienced individuals
    Marie I. Samanovic, Amber R. Cornelius, Sophie L. Gray-Gaillard, Joseph R. Allen, Trishala Karmacharya, Jimmy P. Wilson, Sara Hyman, Michael Tuen, Sergei B. Koralov, Mark J. Mulligan et al. · 2022 · Science Translational Medicine
  19. SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
    P. Van Caeseele, D. Bailey, Sarah E. D. Forgie, T. Dingle, M. Krajden · 2020 · Canadian Medical Association Journal
  20. Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling
    J. S. Bednash, V. Kagan, J. Englert, D. Farkas, Y. Tyurina, V. Tyurin, S. Samovich, L. Farkas, Ajit Elhance, F. Johns et al. · 2021 · Translational Research: The Journal of Laboratory and Clinical Medicine
  21. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses
    Jared E. Feldman, Julia Bals, Clara G. Altomare, Kerri St. Denis, Evan Christopher Lam, Blake Marie Hauser, Larance Ronsard, Maya Sangesland, Thalia Bracamonte Moreno, Vintus Okonkwo et al. · 2021 · Science Immunology
  22. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma
    William N. Voss, Y. Hou, N. Johnson, Jin Eyun Kim, George Delidakis, Andrew P. Horton, Foteini Bartzoka, Chelsea J. Paresi, Yuri Tanno, Shawn A. Abbasi et al. · 2020 · bioRxiv
  23. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects
    Jiaxin Zheng, Yingying Deng, Zhenyu Zhao, Binli Mao, Meng-Ji Lu, Yong Lin, Ai-long Huang · 2021 · Cellular & Molecular Immunology
  24. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
    I. Cassaniti, E. Percivalle, F. Bergami, A. Piralla, G. Comolli, R. Bruno, M. Vecchia, M. Sambo, M. Colaneri, V. Zuccaro et al. · 2021 · Clinical Microbiology and Infection
  25. COVID-19 neutralizing antibodies predict disease severity and survival
    W. Garcia-Beltran, E. Lam, M. Astudillo, Diane Yang, T. Miller, J. Feldman, B. Hauser, Timothy M. Caradonna, K. Clayton, Adam D. Nitido et al. · 2020 · Cell
  26. SARS-CoV-2 viral dynamics in non-human primates
    Antonio Gonçalves, P. Maisonnasse, F. Donati, Mélanie Albert, S. Behillil, V. Contreras, Thibaut Naninck, R. Marlin, C. Solas, A. Pizzorno et al. · 2021 · PLoS Comput. Biol.
  27. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan -implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
    Tao Liu, Sanyun Wu, Huangheng Tao, Guang Zeng, Fuling Zhou, F. Guo, Xing-Huan Wang · 2020 · medRxiv
  28. New IgM seroconversion and positive RT‐PCR test after exposure to the virus in recovered COVID‐19 patient
    E. Bentivegna, A. Sentimentale, M. Luciani, M. Speranza, L. Guerritore, P. Martelletti · 2020 · Journal of Medical Virology
  29. Re-starting travel in the era of COVID-19: preparing anew
    M. Wilson, Lin H. Chen · 2020 · Journal of Travel Medicine
  30. Persistence of humoral immune response to SARS-CoV-2 up to 7 months post-infection: Cross-sectional study, South India, 2020–21
    L. Pezzati, A. Giacomelli, D. Mileto, F. Conti, Gloria Gagliardi, A. Rizzo, Laura Milazzo, M. Schiuma, A. Covizzi, M. Siano et al. · 2021 · medRxiv
  31. Adaptive immunity to SARS-CoV-2
    D. Altmann · 2020 · Oxford Open Immunology
  32. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
    M. Brustolin, J. Rodón, M. L. Rodríguez de la Concepción, C. Ávila-Nieto, G. Cantero, M. Pérez, Nigeer Te, M. Noguera-Julián, V. Guallar, Alfonso Valencia et al. · 2021 · Emerging Microbes and Infections
  33. Serum antibody profile of a patient with COVID-19 reinfection
    K. To, I. Hung, K. Chan, Shuo-Feng Yuan, Wing-Kin To, D. Tsang, V. Cheng, Zhi-Wei Chen, Kin-Hang Kok, Kwok Y. Yuen · 2020 · Clinical Infectious Diseases
  34. Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development
    Yue-Fei Zhu, Jia Li, Z. Pang · 2020 · Asian Journal of Pharmaceutical Sciences
  35. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
    E. Abebe, T. Dejenie · 2023 · Frontiers in Immunology
  36. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys
    C. Le Nouën, Christine E. Nelson, Xue-Qiao Liu, Hong-Su Park, Y. Matsuoka, Cindy Luongo, Celia Santos, Li-Juan Yang, Richard Herbert, Ashley Castens et al. · 2022 · Cell
  37. SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant
    P. Yadav, S. Mohandas, A. Shete, Dimpal A. Nyayanit, Nivedita Gupta, D. Patil, G. Sapkal, V. Potdar, M. Kadam, Abhimanyu Kumar et al. · 2021 · bioRxiv
  38. Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus
    C. T. Ekanger, Fan Zhou, Dana Bohan, Maria L. Lotsberg, M. Ramnefjell, L. Hoareau, G. Røsland, Ning Lu, M. Aanerud, F. Gärtner et al. · 2022 · Frontiers in Cellular and Infection Microbiology
  39. Insights into SARS-CoV-2 Persistence and Its Relevance
    Belete Ayele Desimmie, Yonas Raru, Hesham Awadh, Peimei He, Samson Teka, Kara S. Willenburg · 2021 · Viruses
  40. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
    Sham Nambulli, Yufei Xiang, N. L. Tilston-Lunel, L. Rennick, Z. Sang, W. Klimstra, D. Reed, N. Crossland, Yi Shi, W. P. Duprex · 2021 · bioRxiv
  41. Predicting infectivity: comparing four PCR‐based assays to detect culturable SARS‐CoV‐2 in clinical samples
    E. Bruce, M. Mills, Reigran Sampoleo, G. Perchetti, Meei-Li W. Huang, Hannah W. Despres, Madaline M. Schmidt, Pavitra Roychoudhury, David J. Shirley, K. Jerome et al. · 2021 · EMBO Molecular Medicine
  42. Nanotraps for the containment and clearance of SARS-CoV-2
    Min Chen, Jillian Rosenberg, Xiaolei Cai, A. Lee, Jiu-Yun Shi, Mindy Nguyen, T. Wignakumar, Vikranth R. Mirle, Arianna Edobor, John F. Fung et al. · 2021 · bioRxiv
  43. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
    J. Jaworski · 2020 · Biomedical Journal
  44. Cell and animal models of SARS-CoV-2 pathogenesis and immunity
    S. Leist, A. Schäfer, David R. Martinez · 2020 · Disease Models & Mechanisms
  45. Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City
    D. Stadlbauer, Jessica Tan, Kai-Jun Jiang, M. Hernandez, Shelcie Fabre, Fatima Amanat, Catherine Teo, Guha Asthagiri Arunkumar, Meagan McMahon, J. Jhang et al. · 2020 · medRxiv
  46. SARS-CoV-2 infection induces protective immunity and limits transmission in Syrian hamsters
    Prabhuanand Selvaraj, Christopher Z. Lien, Shu-Feng Liu, C. Stauft, Ivette A Nuñez, M. Hernandez, E. Nimako, M. A. Ortega, M. Starost, J. Dennis et al. · 2021 · Life Science Alliance
  47. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
    K. Böszörményi, M. Stammes, Zahra C. Fagrouch, Gwendoline Kiemenyi-Kayere, H. Niphuis, D. Mortier, N. van Driel, I. Nieuwenhuis, R. Vervenne, T. Haaksma et al. · 2020 · Viruses
  48. ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics
    J. A. Hewitt, C. Lutz, William C. Florence, M. L. Pitt, Srinivas Rao, Jay Rappaport, N. Haigwood · 2020 · Cell Host and Microbe
  49. Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection
    Kun Han, R. Blair, N. Iwanaga, Feng-Ming Liu, K. Russell-Lodrigue, Zhong-Hua Qin, C. Midkiff, Nadia A. Golden, L. Doyle-Meyers, M. E. Kabir et al. · 2020 · American Journal of Respiratory Cell and Molecular Biology
  50. Generation of a Novel SARS-CoV-2 Sub-genomic RNA Due to the R203K/G204R Variant in Nucleocapsid: Homologous Recombination has Potential to Change SARS-CoV-2 at Both Protein and RNA Level
    Shay Leary, S. Gaudieri, Matthew D. Parker, A. Chopra, I. James, S. Pakala, Eric Alves, M. John, B. Lindsey, A. Keeley et al. · 2021 · Pathogens and Immunity
  51. Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats
    L. Bao, Zhi-Qi Song, Jing Xue, Hong Gao, Jiang-Ning Liu, Jie Wang, Qian Guo, Bin-Bin Zhao, Ya-Jin Qu, Fei-Fei Qi et al. · 2021 · Journal of Infectious Diseases
  52. Experimental re-infected cats do not transmit SARS-CoV-2
    N. Gaudreault, Mariano Carossino, I. Morozov, J. Trujillo, D. Meekins, Daniel W. Madden, K. Cool, B. Artiaga, Chester D. McDowell, D. Bold et al. · 2021 · bioRxiv
  53. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition
    Röltgen, Katharina, Nielsen, Sandra C. A., Arunachalam, Prabhu S., Yang, Fan, Hoh, Ramona A., Wirz, Oliver F., Lee, Alexandra S., Gao, Fei, Mallajosyula, Vamsee, Li, Chunfeng et al. · 2021
  54. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
    Jing-You Yu, Lisa H. Tostanoski, N. Mercado, K. McMahan, Jin-Yan Liu, Catherine Jacob-Dolan, A. Chandrashekar, C. Atyeo, David R. Martinez, Tochi Anioke et al. · 2021 · Nature
  55. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
    Corbett, Kizzmekia S., Nason, Martha C., Flach, Britta, Gagne, Matthew, O’ Connell, Sarah, Johnston, Timothy S., Shah, Shruti N., Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin et al. · 2021
  56. Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study
    A. Abdoli, R. Aalizadeh, Hossein Aminianfar, Z. Kianmehr, A. Teimoori, E. Azimi, Nabbi Emamipour, M. Eghtedardoost, Vahid Siavashi, H. Jamshidi et al. · 2021 · Reviews in Medical Virology
  57. Non-human primate models of human respiratory infections
    Julien Lemaître, Thibaut Naninck, B. Delache, J. Creppy, P. Huber, Marion Holzapfel, Camille Bouillier, V. Contreras, F. Martinon, Nidhal Kahlaoui et al. · 2021 · Molecular Immunology
  58. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020)
    David S. Kim, S. Rowland-Jones, E. Gea-Mallorquí · 2020 · Frontiers in Immunology
  59. SARS-CoV-2 in animals: From potential hosts to animal models
    Anna Michelitsch, K. Wernike, Lorenz Ulrich, T. Mettenleiter, M. Beer · 2021 · Advances in Virus Research
  60. Mechanisms of SARS-CoV-2-induced lung vascular disease: potential role of complement
    K. Stenmark, M. Frid, E. Gerasimovskaya, Hui Zhang, M. McCarthy, J. Thurman, T. Morrison · 2021 · Pulmonary Circulation
  61. Immunity to SARS-CoV-2: Lessons Learned
    JAIME E. FERGIE, Amit K. Srivastava · 2021 · Frontiers in Immunology
  62. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
    C. Beltrán-Pavez, S. Riquelme-Barrios, A. Oyarzún-Arrau, A. Gaete-Argel, R. González-Stegmaier, Karina Cereceda-Solis, A. Aguirre, D. Travisany, R. Palma-Véjares, Gonzalo P. Barriga et al. · 2021 · Science Advances
  63. SARS-CoV-2 antibody testing for estimating COVID-19 prevalence in the population
    Thomas J. Vogl, Sigal Leviatan, Eran Segal · 2021 · Cell Reports Medicine
  64. Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic
    T. Baggett, J. A. Scott, Mylinh H. Le, F. Shebl, Christopher Panella, E. Losina, Clare F. Flanagan, Jessie M. Gaeta, Anne M. Neilan, Emily P. Hyle et al. · 2020 · JAMA Network Open
  65. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)
    Bindu M. Bennet, J. Wolf, R. Laureano, R. Sellers · 2020 · Toxicologic pathology (Print)
  66. The Consequences of COVID-19 and Other Disasters for Wildlife and Biodiversity
    Daniel Rondeau, B. Perry, Franque Grimard · 2020 · Environmental and Resource Economics
  67. The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
    G. Ahlén, L. Frelin, N. Nikouyan, F. Weber, U. Höglund, O. Larsson, M. Westman, Ola Tuvesson, E. Gidlund, Matteo Cadossi et al. · 2020 · Journal of Virology
  68. Immunity Elicited by Natural Infection or Ad26.COV2.S Vaccination Protects Hamsters Against SARS-CoV-2 Variants of Concern
    Lisa H. Tostanoski, Jing-You Yu, N. Mercado, K. McMahan, Catherine Jacob-Dolan, Amanda J. Martinot, C. Piedra-Mora, Tochi Anioke, Aiquan Chang, Victoria M. Giffin et al. · 2021 · Science Translational Medicine
  69. SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage
    Y. Sui, Jianping Li, D. Venzon, J. Berzofsky · 2021 · Frontiers in Immunology
  70. Human-Based Advanced in vitro Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19
    Mirjam Kiener, Nuria Roldán, Carlos Machahua, Arunima Sengupta, Thomas Geiser, Olivier T. Guenat, Manuela Funke-Chambour, Nina Hobi, Marianna Kruithof‐de Julio · 2021 · Frontiers in Medicine
  71. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines
    Julio Villena, Chang Li, María Guadalupe Vizoso-Pinto, Jacinto Sacur, Linzhu Ren, Haruki Kitazawa · 2021 · Microorganisms
  72. SARS-CoV-2 Rapidly Adapts in Aged BALB/c Mice and Induces Typical Pneumonia
    Yu-Fei Zhang, Kun Huang, Ting Wang, F. Deng, Wenxiao Gong, Xian-Feng Hui, Ya Zhao, Xinlin He, Chengfei Li, Qiang Zhang et al. · 2021 · Journal of Virology
  73. Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
    Chao Hu, M. Shen, Xiao-Jian Han, Qian Chen, Luo Li, Si-Yin Chen, Jing Zhang, Feng-xia Gao, Wen Wang, Ying-Ming Wang et al. · 2020 · bioRxiv
  74. Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species
    Matthew R. Alexander, Clara T. Schoeder, Jacquelyn A. Brown, C. Smart, C. Moth, J. Wikswo, J. Capra, J. Meiler, Wen-Biao Chen, Meena S. Madhur · 2020 · The FASEB Journal
  75. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
    Carolin Loos, C. Atyeo, S. Fischinger, John S. Burke, Matthew D. Slein, H. Streeck, D. Lauffenburger, E. Ryan, R. Charles, G. Alter · 2020 · Msphere
  76. COVID ‐19 and plasma cells: Is there long‐lived protection?*
    Doan C. Nguyen, Pedro A. Lamothe, Matthew Charles Woodruff, Ankur Singh Saini, Caterina Elisa Faliti, Igñacio Sanz, Frances Eun-Hyung Lee · 2022 · Immunological Reviews
  77. Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
    Mar Masiá, Marta Fernández‐González, Guillermo Telenti, Vanesa Agulló, José Alberto García, Sergio Padilla, Javier García‐Abellán, Antonio Galiana, Nieves Gonzalo-Jiménez, Félix Gutiérrez · 2021 · Journal of Autoimmunity
  78. COVID-19, the first pandemic in the post-genomic era
    Lucy van Dorp, Charlotte J. Houldcroft, Damien Richard, François Balloux · 2021 · Current Opinion in Virology
  79. Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
    R. Pellini, A. Venuti, F. Pimpinelli, E. Abril, G. Blandino, Flaminia Campo, L. Conti, A. de Virgilio, Federico De Marco, E. D. Di Domenico et al. · 2021 · Vaccines
  80. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection
    Z. Khoshkam, Y. Aftabi, P. Stenvinkel, B. P. Lawrence, M. Rezaei, G. Ichihara, S. Fereidouni · 2021 · Journal of Advanced Research
  81. COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions
    E. Urano, T. Okamura, Chikako Ono, Shiori Ueno, S. Nagata, H. Kamada, Mahoko Higuchi, Mugi Furukawa, W. Kamitani, Y. Matsuura et al. · 2021 · Proceedings of the National Academy of Sciences of the United States of America
  82. A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques
    Paul E. Harris, T. Brasel, C. Massey, C. Herst, Scott R. Burkholz, P. Lloyd, Tikoes Blankenberg, Thomas M. Bey, R. Carback, Tom Hodge et al. · 2021 · bioRxiv
  83. Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review
    Salleh N. Ehaideb, Mashan L. Abdullah, Bisher Abuyassin, Abderrezak Bouchama · 2020 · Critical Care
  84. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study
    I. Molodtsov, Evgenii Kegeles, A. Mitin, O. Mityaeva, O. Musatova, A. Panova, M. Pashenkov, I. Peshkova, Almaqdad Alsalloum, W. Asaad et al. · 2022 · Clinical Infectious Diseases
  85. Experimental Inoculation of Young Calves with SARS-CoV-2
    Shollie M. Falkenberg, A. Buckley, Melissa Laverack, Mathias Martins, M. Palmer, K. Lager, D. Diel · 2021 · Viruses
  86. SARS-CoV-2 failure to infect or replicate in mosquitoes: an extreme challenge
    Yan-Jang S. Huang, D. Vanlandingham, Ashley N. Bilyeu, Haelea M. Sharp, S. Hettenbach, S. Higgs · 2020 · Scientific Reports
  87. Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues
    Christine E. Nelson, S. Namasivayam, Taylor W. Foreman, Keith D. Kauffman, Shunsuke Sakai, Danielle E. Dorosky, N. Lora, Kelsie Brooks, E. L. Potter, N. Garza et al. · 2022 · bioRxiv
  88. Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques
    Xuan He, A. Chandrashekar, R. Zahn, F. Wegmann, Jing-You Yu, N. Mercado, K. McMahan, Amanda J. Martinot, C. Piedra-Mora, Sidney Beecy et al. · 2021 · bioRxiv
  89. Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients
    O. Brook, Kimberly G. Piper, N. Mercado, Makda S. Gebre, D. Barouch, K. Busman-Sahay, C. Starke, J. Estes, Amanda J. Martinot, Linda M. Wrijil et al. · 2020 · Abdominal Radiology
  90. Early Epidemiological Features of COVID-19 in Nepal and Public Health Response
    S. Dhakal, S. Karki · 2020 · Frontiers in Medicine
  91. Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden
    Xaquín Castro Dopico, Sandra Muschiol, Murray Christian, Leo Hanke, Daniel J. Sheward, Nastasiya F. Grinberg, Joanna Rorbach, Gordana Bogdanović, Gerald M. McInerney, Tobias Allander et al. · 2021 · Journal of Internal Medicine
  92. Cell-Type Apoptosis in Lung during SARS-CoV-2 Infection
    Ya-Kun Liu, Tania M Garron, Q. Chang, Zhengchen Su, Changcheng Zhou, Yuan Qiu, Eric C. Gong, Jun-Ying Zheng, Y. Yin, T. Ksiazek et al. · 2021 · Pathogens
  93. SARS-CoV-2 vaccine candidates in rapid development
    Li-Feng Li, Pengbo Guo, Xiaoman Zhang, Zhi-Dan Yu, Wan-Cun Zhang, Hui-Qing Sun · 2020 · Human Vaccines & Immunotherapeutics
  94. Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases
    Ziyang Xu, Ami R. Patel, Nicholas J. Tursi, Xi-Zhou Zhu, K. Muthumani, Daniel W. Kulp, D. Weiner · 2020 · Frontiers in Medical Technology
  95. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
    R. Marlin, V. Godot, Sylvain Cardinaud, Mathilde Galhaut, Séverin Coléon, S. Zurawski, N. Dereuddre-Bosquet, M. Cavarelli, Anne-Sophie Gallouët, P. Maisonnasse et al. · 2021 · Nature Communications
  96. Selection of animal models for COVID-19 research
    Suresh Kumar, P. Yadav, R. Srinivasan, N. Perumal · 2020 · VirusDisease
  97. Dynamics of viral load and anti-SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19
    K. Song, Dong-Min Kim, Hyunju Lee, S. Ham, S. Oh, Hyeonju Jeong, Jongtak Jung, C. K. Kang, J. Y. Park, Y. Kang et al. · 2020 · The Korean Journal of Internal Medicine
  98. Experimental Models for the Study of Central Nervous System Infection by SARS-CoV-2
    I. Sanclemente-Alamán, L. Moreno-Jiménez, M. S. Benito-Martín, A. Canales-Aguirre, J. Matias-Guiu, J. Matías-Guíu, U. Gómez-Pinedo · 2020 · Frontiers in Immunology
  99. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level
    Shay Leary, S. Gaudieri, Matthew D. Parker, A. Chopra, I. James, S. Pakala, Eric Alves, M. John, B. Lindsey, A. Keeley et al. · 2020 · bioRxiv
  100. SARS-CoV-2 immunity in animal models
    Zhaoming Chen, Yaochang Yuan, Qingtao Hu, Ai-Ru Zhu, Fenghua Chen, Shu Li, Xin Guan, Chao Lv, Tian Tang, Yi-Yun He et al. · 2024 · Cellular & Molecular Immunology